PsychonautWiki Archive

25B-NBOMe: Difference between revisions

← Older edit
>Kenan
m fix property
>Graham
 
(19 intermediate revisions by 12 users not shown)
Line 1: Line 1:
[[SubstanceClassAlias::25x-NBOMe| ]]
<br />
{{Headerpanel|{{Warning/25B-NBOMe}}}}
{{Headerpanel|{{Warning/25B-NBOMe}}}}
{{SummarySheet}}
{{SummarySheet}}
{{SubstanceBox/25B-NBOMe}}
{{SubstanceBox/25B-NBOMe}}
'''25B-NBOMe''' (also known as '''Cimbi-36''', '''NBOMe-2C-B''' and '''2C-B-NBOMe''') is novel [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] class. It is a member of the 25x-NBOMe series, a recently discovered group of potent psychedelic compounds derived from the [[2C-x]] family. The name 25B-NBOMe, which is short-hand for 2C-B-NBOMe, indicates it is a derivative of the phenethylamine psychedelic 2C-B.


'''25B-NBOMe''' (also known as '''Cimbi-36''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].  
25B-NBOMe was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref name="Heim2004">{{cite journal | vauthors=((Heim, R.)) | title=Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts | date= 2004 | language=german | url=https://refubium.fu-berlin.de/handle/fub188/11995 | doi=10.17169/refubium-16193}}</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">{{cite journal | vauthors=((Hansen, M.)), ((Phonekeo, K.)), ((Paine, J. S.)), ((Leth-Petersen, S.)), ((Begtrup, M.)), ((Bräuner-Osborne, H.)), ((Kristensen, J. L.)) | journal=ACS Chemical Neuroscience | title=Synthesis and Structure–Activity Relationships of N -Benzyl Phenethylamines as 5-HT 2A/2C Agonists | volume=5 | issue=3 | pages=243–249 | date=19 March 2014 | url=https://pubs.acs.org/doi/10.1021/cn400216u | issn=1948-7193 | doi=10.1021/cn400216u}}</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" /> This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}}


The name 25B-NBOMe, which short-hand for 2C-B-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-B]]. It was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref>Ralf Heim (February 28, 2010). [http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts."] (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMID 24397362. https://doi.org/10.1021/cn400216u</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" />
[[Subjective effects]] include [[stimulation]], [[geometry|open and closed-eye visuals]], [[time distortion]], [[euphoria]], and [[ego loss]]. Anecdotal reports suggest 25B-NBOMe to be an active [[hallucinogen]] at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived [[hallucinogens]] such as [[Bromo-DragonFLY]].<ref>{{Citation | title=Erowid Bromo-Dragonfly Vault : Dosage | url=https://erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_dose.shtml}}</ref> It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] class are not [[oral|orally]] active and should therefore be taken [[sublingual|sublingually]] by placing them into one's mouth and allowing it to absorb over a period of 15-30 minutes.


Anecdotal reports from users suggest 25B-NBOMe to be an active [[hallucinogen]] at a dose of as little as 250–500 µg, making it a similar potency to other phenethylamine derived [[hallucinogens]] such as [[Bromo-DragonFLY]].<ref>Bromo-Dragonfly Dosage by Erowid | https://erowid.org/chemicals/bromo_dragonfly/bromo_dragonfly_dose.shtml</ref> It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] class are not [[oral|orally]] active and should therefore be taken [[sublingual|sublingually]] by placing the substance into one's mouth and allowing it to slowly absorb over a period of 15-30 minutes.
Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25B-NBOMe in humans. Numerous members of the [[25x-NBOMe]] series have been associated with hospitalizations and deaths. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to use [[harm reduction practices]] if using this substance.
 
This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}} Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25B-NBOMe in humans, and numerous members of the [[25x-NBOMe]] series have been associated with hospitalizations and deaths. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood, potentially deadly [[psychedelic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it.


==Chemistry==
==Chemistry==
[[File:25bnbome_and_2cb.png|250px|thumb|right|A comparison of 25B-NBOMe and 2C-B.]]
[[File:25bnbome_and_2cb.png|250px|thumb|right|A comparison of 25B-NBOMe and 2C-B.]]
25B-NBOMe or 2C-B-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as [[2C-B]]. 25B-NBOMe is a substituted phenethylamine with methoxy groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a bromine atom attached to carbon R<sub>4</sub>. It differs from [[2C-B]] structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. 25B-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH<sub>3</sub>O- bound to a benzene ring at R<sub>2</sub>.
25B-NBOMe or 2C-B-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as [[2C-B]]. 25B-NBOMe is a substituted phenethylamine with methoxy groups CH<sub>3</sub>O- attached to carbons R<sub>2</sub> and R<sub>5</sub> as well as a bromine atom attached to carbon R<sub>4</sub>. It differs from [[2C-B]] structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. 25B-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH<sub>3</sub>O- bound to a benzene ring at R<sub>2</sub>.
The compound has a density of 1.3 (±0.1) g/cm^3.


==Pharmacology==
==Pharmacology==
{{Further|Serotonergic psychedelic}}
{{Further|Serotonergic psychedelic}}
25B-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|partial agonist]].<ref>Synthesis and pharmacology of potent 5-HT 2A receptor agonists with N-2-methoxybenzyl partial structure | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221</ref><ref>Theoretical study of the interaction of agonists with the 5-HT2A receptor | http://epub.uni-regensburg.de/12119/</ref><ref>Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor | http://link.springer.com/article/10.1007%2Fs10822-010-9400-2</ref><ref>Synthesis and Structure–Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists | http://pubs.acs.org/doi/abs/10.1021/cn400216u</ref> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.
25B-NBOMe has efficacy at the [[serotonin#The 5-HT system|5-HT<sub>2A</sub> receptor]] where it acts as a potent [[Agonist#Agonists|partial agonist]].<ref name="Heim2004"/><ref>{{cite journal | vauthors=((Silva, Maria Elena)) | title=Theoretical study of the interaction of agonists with the 5-HT2A receptor | date= 2009 | url=https://epub.uni-regensburg.de/id/eprint/12119 | doi=10.5283/EPUB.12119}}</ref><ref>{{cite journal | vauthors=((Silva, M. E.)), ((Heim, R.)), ((Strasser, A.)), ((Elz, S.)), ((Dove, S.)) | journal=Journal of Computer-Aided Molecular Design | title=Theoretical studies on the interaction of partial agonists with the 5-HT2A receptor | volume=25 | issue=1 | pages=51–66 | date= January 2011 | url=http://link.springer.com/10.1007/s10822-010-9400-2 | issn=0920-654X | doi=10.1007/s10822-010-9400-2}}</ref><ref name="25BSAR"/> However, the role of these interactions and how they result in the [[psychedelic]] experience continues to remain elusive.


==Subjective effects==
==Subjective effects==
Line 89: Line 90:
===Experience reports===
===Experience reports===
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here:
* [https://www.erowid.org/experiences/subs/exp_25BNBOMe.shtml Erowid Experience Vaults: 25B-NBOMe]
 
*[https://www.erowid.org/experiences/subs/exp_25BNBOMe.shtml Erowid Experience Vaults: 25B-NBOMe]


==Toxicity and harm potential==
==Toxicity and harm potential==
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
{{further|Research chemicals#Toxicity and harm potential|Responsible use #Hallucinogens}}
25B-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The lethal dosage has not yet been determined. One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy.<ref>Designer Drug Identified As Cause Of Plano Teen’s Death | http://dfw.cbslocal.com/2015/02/19/designer-drug-identified-as-cause-of-plano-teens-death/</ref>
25B-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The lethal dosage has not yet been determined. One case has been reported on where 25B-NBOMe was identified as the cause of death for a 17-year-old boy.<ref>{{Citation | title=Designer Drug Identified As Cause Of Plano Teen’s Death | url=https://www.cbsnews.com/dfw/news/designer-drug-identified-as-cause-of-plano-teens-death/}}</ref>


It is advised that due to 25B-NBOMe's extreme potency it should not be insufflated as this method of administration is [[Toxicity::potentially fatal at heavy dosages]].<ref>http://www.erowid.org/chemicals/nbome/nbome_death.shtml</ref>  
It is advised that due to 25B-NBOMe's extreme potency it should not be insufflated as this method of administration is [[Toxicity::potentially fatal at heavy dosages]].<ref name="25Xfatal">{{Citation | title=Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths | url=https://www.erowid.org/chemicals/nbome/nbome_death.shtml}}</ref>  


25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram; Such a dose is 300× lower than the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans.<ref>Preclinical Safety Assessment of the 5-HT2A
25B-NBOMe has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram; Such a dose is 300× lower than the dose expected to be hallucinogenic to humans and it is expected that recreational use would greatly exceed doses determined to be safe to humans.<ref>Preclinical Safety Assessment of the 5-HT2A
Line 103: Line 105:


===Tolerance and addiction potential===
===Tolerance and addiction potential===
25B-NBOMe is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.  
25B-NBOMe is [[Addiction potential::not habit-forming]], and the desire to use it can actually decrease with use. It is most often self-regulating.
 
Tolerance to the effects of 25B-NBOMe is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back at baseline (in the absence of further consumption). 25B-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25B-NBOMe all psychedelics will have a reduced effect.


Tolerance to the effects of 25B-NBOMe are built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back at baseline (in the absence of further consumption). 25B-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25B-NBOMe all psychedelics will have a reduced effect.
===Overdose===
{{NBOMeOD}}


===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions}}
{{DangerousInteractions/Intro}}
{{DangerousInteractions/NBOMe}}


Although many substances are safe on their own, they can become dangerous and even life-threatening when combined with other substances. The list below contains some common potentially dangerous combinations, but may not include all of them. Certain combinations may be relatively harmless in low doses of each but can still increase the risk of unpredictable injury or death. [https://www.google.com/ Independent research] should always be done to ensure that a combination of two or more substances is safe before consumption.
==Legal status==


*'''[[Tramadol]]''' - Tramadol lowers the seizure threshold<ref>Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. https://doi.org/10.1007/BF03161089</ref> and [[psychedelics]] may act as triggers for seizures, particularly in those who are predisposed to them.{{citation needed}}
*'''Austria''': Since June 26, 2019, 25B-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
*'''[[Stimulants]]''' - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable [[anxiety]], [[Panic attacks|panic]], [[thought loops]] and [[paranoia]]. This interaction may cause elevated risk of psychosis.{{citation needed}}
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''[https://en.wikipedia.org/wiki/Lithium_(medication) Lithium]''' - Lithium is often used as treatment for bipolar disorder. It may possibly cause elevated risk of seizures and psychosis due to its [[Glutamate|glutaminergic]] and [[GABA|GABAergic]] effects.{{citation needed}}
*'''Canada''': 25B-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>{{Citation | vauthors=((Branch, L. S.)) | year=2022 | title=Consolidated federal laws of Canada, Controlled Drugs and Substances Act | url=https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html}}</ref>
*'''China''': As of October 2015, 25B-NBOMe is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''Germany''': 25B-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of December 13, 2014.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl114s1999.pdf%27%5D__1576023093735|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 11, 2019|language=de}}</ref><ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Anlage I BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref>
*'''Italy''': 25B-NBOMe is a Schedule 1 controlled substance in Italy.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref>
*'''Japan''': 25B-NBOMe is a narcotic drug in Japan effective November 1st, 2015.<ref>[https://www.mhlw.go.jp/stf/houdou/0000098723.html "新たに４物質を麻薬に指定し、規制の強化を図ります"] (in Japanese). 厚生労働省 [Ministry of Health, Labour and Welfare (MHLW)]. Retrieved May 2, 2022.</ref>
*'''Latvia''': 25B-NBOMe is a Schedule I controlled substance.<ref>{{Citation | title=Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem | url=https://likumi.lv/doc.php?id=121086}}</ref>
*'''New Zealand''': 25B-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>{{Citation | title=Misuse of Drugs Act 1975 No 116 (as at 07 December 2021), Public Act – New Zealand Legislation | url=https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html}}</ref>
*'''Sweden''': 25B-NBOMe is classed as Schedule I.<ref>{{Citation | title=Läkemedelsverkets författningssamling | url= http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf}}</ref>
*'''Switzerland''': 25B-NBOMe is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Turkey:''' 25B-NBOMe is a classed as drug and is illegal to possess, produce, supply, or import.<ref name="Bakanlar Kurulu Kararı - Karar Sayısı : 2013/5742">{{Citation | title=Başbakanlık Mevzuatı Geliştirme ve Yayın Genel Müdürlüğü | url=https://resmigazete.gov.tr/eskiler/2014/01/20140125-3.htm}}</ref> <ref name="List of illegal substances for law"> https://resmigazete.gov.tr/eskiler/2014/01/20140125-3-1.pdf</ref>
*'''United Kingdom''': 25B-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>{{Citation | year=2014 | title=Misuse of Drugs Act 1971 (S.I. 2014/1106) | publisher=London: The Stationery Office Limited | url=https://www.legislation.gov.uk/uksi/2014/1106/made | access-date=5 July 2017}}</ref>
*'''United States''': On Nov 15, 2013, the DEA added 25B-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>


==Legality==
==See also==
*'''Austria:''' 25B-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).{{citation needed}}
*'''Brazil''' - Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''China:''' As of October 2015 25B-NBOMe is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref>
*'''Germany''' - Possession, production and sale is illegal.<ref>BtMG Anlage I | https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html </ref>
*'''United Kingdom''' - 25B-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref>
*'''Sweden:''' 25B-NBOMe is classed as Schedule I.<ref>Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf</ref>
*'''United States:''' On Nov 15, 2013, the DEA added 25B-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>
*'''Latvia:''' 25B-NBOMe is a Schedule I controlled substance.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''New Zealand:''' 25B-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>
*'''Canada:''' 25B-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
*'''Italy:''' In Italy 25B-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref>


==See also==
*[[Responsible use]]
*[[Responsible use]]
*[[Research chemical]]
*[[Research chemical]]
Line 137: Line 142:


==External links==
==External links==
*[https://en.wikipedia.org/wiki/25B-NBOMe 25B-NBOMe (Wikipedia)]
*[https://en.wikipedia.org/wiki/25B-NBOMe 25B-NBOMe (Wikipedia)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5526 25B-NBOMe (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5526 25B-NBOMe (Isomer Design)]
Line 143: Line 149:
==References==
==References==
<references />
<references />
[[Category:Psychoactive substance]]
[[Category:Psychoactive substance]]
[[Category:Psychedelic]]
[[Category:25x-NBOMe]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Phenethylamine]]
 
[[Category:Psychedelic]]
{{#set:Featured=true
{{#set:Featured=true
|RN=CH₂-C₆H₄-OCH₃
|RN=CH₂-C₆H₄-OCH₃
Retrieved from "http://psy.st/wiki/25B-NBOMe"